Distributors in western Pennsylvania are optimistic a couple of doable Johnson & Johnson vaccine

The supply of COVID-19 vaccines remains inadequate. Desperate patients include Jackie Cramer and her 94-year-old mother Mary. Jackie says she tried everything with no luck. “I just want my recordings for myself and my mother. Is that too much to ask?” Cramer said: Two vaccines are currently on the market; Pfizer and Moderna. But a third could be on the way courtesy of Johnson and Johnson. The company submitted its data to the Food and Drug Administration for approval last week. The FDA board will meet on February 26th to decide whether or not to approve the use. Pfizer vaccines ran out just three days after approval in mid-December. Health officials say they are hopeful and optimistic about this vaccine. The vaccine is only one dose and does not require special refrigeration. Vic Vercammen is the Chief Pandemic Officer for Giant Eagle Pharmacy: “This will certainly improve our flexibility. Hopefully add to the offerings. Hopefully the fact that it is a single shot will help patients don’t necessarily have to come back for that second dose. ” Vercammen said: In the data submitted to the FDA, the vaccine showed an efficacy rate of around 65%, while Moderna and Pfizer’s vaccines were in the mid-1990s. UPMC and Allegheny Health Network, and Allegheny County’s Director of Health, Dr. Debra Bogen, you say a closer look at the numbers tells a great story: “If you look at the data, Johnson and Johnson’s vaccine was 100 percent effective in reducing hospitalizations and deaths,” said Bogen. UPMC and Allegheny Health Netw both say Pittsburgh’s Action News 4 that the launch of this vaccine will improve the overall picture of people’s protection. “A single-dose vaccine would introduce fewer operational challenges, which would be very important in certain environments to maximize access to vaccination in all of our communities,” Allegheny Health Network said in a statement. UPMC adds that “a vaccine that is” only 60-80% effective is still valuable. ”

The supply of COVID-19 vaccines continues to be poor.

Those desperate for a dose include Jackie Cramer and her 94-year-old mother Mary.

Jackie says she tried everything with no luck.

“I just want my recordings for myself and my mother. Is that too much to ask?” Said Cramer.

There are currently two vaccines on the market. Pfizer and Moderna.

But a third could be on the way courtesy of Johnson and Johnson.

The company submitted its data to the Food and Drug Administration for approval last week. The FDA board will meet on February 26th to decide whether or not to approve the use. Pfizer vaccines ran out just three days after approval in mid-December.

Public health officials say they are hopeful and optimistic about this vaccine.

The vaccine is only one dose and does not require special refrigeration.

Vic Vercammen is the Chief Pandemic Officer for Giant Eagle Pharmacy:

“That will certainly improve our flexibility. Hopefully the range will be expanded. Hopefully the fact that it is a single shot will help patients. They can plan a little better and don’t necessarily have to come back for that second dose,” said Vercammen.

In the data submitted to the FDA, the vaccine showed an efficacy rate of around 65% while the vaccines from Moderna and Pfizer were in the mid-1990s.

UPMC and Allegheny Health Network, and Allegheny County’s Director of Health, Dr. Debra Bogen, however, say that a closer look at the numbers tells a great story.

“If you look closely at the data, the Johnson and Johnson vaccine was 100 percent effective in reducing hospital stays and deaths,” said Bogen.

UPMC and Allegheny Health Network announce to Pittsburgh’s Action News 4 that the launch of this vaccine will improve the overall picture of human protection.

“A single-dose vaccine would create fewer operational challenges, which would be very important in certain situations to maximize access to vaccination in all of our communities,” said a statement from the Allegheny Health Network.

UPMC adds that “a vaccine that is” only “60-80% effective is still valuable.”

Comments are closed.